Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

416 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prevalence of infection among asymptomatic and paucisymptomatic contact persons exposed to Ebola virus in Guinea: a retrospective, cross-sectional observational study.
Diallo MSK, Rabilloud M, Ayouba A, Touré A, Thaurignac G, Keita AK, Butel C, Kpamou C, Barry TA, Sall MD, Camara I, Leroy S, Msellati P, Ecochard R, Peeters M, Sow MS, Delaporte E, Etard JF; Contactebogui Study Group. Diallo MSK, et al. Among authors: leroy s. Lancet Infect Dis. 2019 Mar;19(3):308-316. doi: 10.1016/S1473-3099(18)30649-2. Epub 2019 Feb 11. Lancet Infect Dis. 2019. PMID: 30765243
Multidisciplinary assessment of post-Ebola sequelae in Guinea (Postebogui): an observational cohort study.
Etard JF, Sow MS, Leroy S, Touré A, Taverne B, Keita AK, Msellati P, Magassouba N, Baize S, Raoul H, Izard S, Kpamou C, March L, Savane I, Barry M, Delaporte E; Postebogui Study Group. Etard JF, et al. Among authors: leroy s. Lancet Infect Dis. 2017 May;17(5):545-552. doi: 10.1016/S1473-3099(16)30516-3. Epub 2017 Jan 14. Lancet Infect Dis. 2017. PMID: 28094208
A 40-Month Follow-Up of Ebola Virus Disease Survivors in Guinea (PostEbogui) Reveals Long-Term Detection of Ebola Viral Ribonucleic Acid in Semen and Breast Milk.
Keita AK, Vidal N, Toure A, Diallo MSK, Magassouba N, Baize S, Mateo M, Raoul H, Mely S, Subtil F, Kpamou C, Koivogui L, Traore F, Sow MS, Ayouba A, Etard JF, Delaporte E, Peeters M; PostEbogui Study Group. Keita AK, et al. Open Forum Infect Dis. 2019 Nov 8;6(12):ofz482. doi: 10.1093/ofid/ofz482. eCollection 2019 Dec. Open Forum Infect Dis. 2019. PMID: 32128327 Free PMC article.
Temporal evolution of the humoral antibody response after Ebola virus disease in Guinea: a 60-month observational prospective cohort study.
Diallo MSK, Ayouba A, Keita AK, Thaurignac G, Sow MS, Kpamou C, Barry TA, Msellati P, Etard JF, Peeters M, Ecochard R, Delaporte E, Toure A; PostEbogui Study Group. Diallo MSK, et al. Lancet Microbe. 2021 Dec;2(12):e676-e684. doi: 10.1016/S2666-5247(21)00170-1. Epub 2021 Sep 3. Lancet Microbe. 2021. PMID: 35544108 Free article.
Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1.
NAMSAL ANRS 12313 Study Group; Kouanfack C, Mpoudi-Etame M, Omgba Bassega P, Eymard-Duvernay S, Leroy S, Boyer S, Peeters M, Calmy A, Delaporte E. NAMSAL ANRS 12313 Study Group, et al. Among authors: leroy s. N Engl J Med. 2019 Aug 29;381(9):816-826. doi: 10.1056/NEJMoa1904340. Epub 2019 Jul 24. N Engl J Med. 2019. PMID: 31339676 Clinical Trial.
Cost-Utility Analysis of a Dolutegravir-Based Versus Low-Dose Efavirenz-Based Regimen for the Initial Treatment of HIV-Infected Patients in Cameroon (NAMSAL ANRS 12313 Trial).
Bousmah MA, Nishimwe ML, Tovar-Sanchez T, Lantche Wandji M, Mpoudi-Etame M, Maradan G, Omgba Bassega P, Varloteaux M, Montoyo A, Kouanfack C, Delaporte E, Boyer S; New Antiretroviral and Monitoring Strategies in HIV-infected Adults in Low-Income Countries (NAMSAL) ANRS 12313 Study Group. Bousmah MA, et al. Pharmacoeconomics. 2021 Mar;39(3):331-343. doi: 10.1007/s40273-020-00987-3. Epub 2020 Dec 23. Pharmacoeconomics. 2021. PMID: 33355914 Free PMC article.
Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon.
Calmy A, Tovar Sanchez T, Kouanfack C, Mpoudi-Etame M, Leroy S, Perrineau S, Lantche Wandji M, Tetsa Tata D, Omgba Bassega P, Abong Bwenda T, Varloteaux M, Tongo M, Mpoudi-Ngolé E, Montoyo A, Mercier N, LeMoing V, Peeters M, Reynes J, Delaporte E; New Antiretroviral and Monitoring Strategies in HIV-infected Adults in Low-Income Countries (NAMSAL) ANRS 12313 Study Group. Calmy A, et al. Among authors: leroy s. Lancet HIV. 2020 Oct;7(10):e677-e687. doi: 10.1016/S2352-3018(20)30238-1. Lancet HIV. 2020. PMID: 33010241 Clinical Trial.
416 results